Spotlight on Hematology
On-Topic Virtual Roundtable™: From R-CHOP to Beyond – Emerging Strategies to Prevent Disease Progression in Patients with Newly Diagnosed DLBCL
StartActivity Details
Expires: February 22, 2023
Jointly Provided By
The Postgraduate Institute for Medicine and Bio Ascend
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with DLBCL.
Learning Objectives
After participating in this activity, participants should be better able to:
- Appraise currently available multiagent chemo-immunotherapy approaches that are traditionally used for the treatment of patients with newly diagnosed DLBCL
- Assess the benefits and limitations of current therapeutic regimens for patients with newly diagnosed DLBCL and the need for novel approaches
- Evaluate the safety and efficacy of clinical trial results evaluating novel approaches to the upfront treatment of patients with DLBCL, including the use of novel agents and combinations
Activity Description
On-Topic Virtual Roundtable™ is an on-demand, accredited continuing education activity featuring three experts who provide expert summary and guidance on the use of current and emerging multiagent treatment regimens for patients with newly diagnosed DLBCL. This roundtable will summarize traditionally used chemo-immunotherapy regimens, limitations with currently available therapies, clinical data of emerging agents and combinations, and strategies for integrating novel regimens into practice as they become available.
Statement of Educational Need
The current standard of care of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in 2021 remains chemo-immunotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Although this modality is safe and effective, up to 45%-50% of patients will relapse. This underscores the need for novel treatment approaches for these patients with newly diagnosed disease. This activity will discuss ongoing efforts to improve upon the standard of care of patients with DLBCL to lengthen progression-free survival (PFS) and improve patient outcomes.
Topics Discussed
- Introduction and Overview of Traditional Regimens
- Limitations of Traditional Therapies
- Emerging Approaches for Frontline Treatment
- Integrating Novel Approaches in Clinical Practice & Key Takeaways
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Gilles Salles, MD, PhD
Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, New York
Consultant: AbbVie, Bayer, BeiGene, BMS/Celgene, Epizyme, Genentech/Roche, Genmab, Incyte, Janssen, Kite/Gilead, Loxo, Milteniy, MorphoSys, Novartis, Rapt, Regeneron, Takeda
Stock Ownership: Owkin

Department Chair, Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Grant/Research Support: AbbVie, Acerta, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, Pharmacyclics, TG Therapeutics, Burroughs Wellcome Fund, CPRIT, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation
Consultant/Advisory Board: AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche, Gilead, Karyopharm, MEI Pharmaceuticals, Pharmacyclics/Janssen, Spectrum

Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Vancouver, Canada
Grant/Research Support: Roche/Genentech, Teva
Consultant/Advisory Board: AbbVie, Acerta, Arigen, Apobiologix, AstraZeneca, Bristol Myers Squibb, Celgene, Gilead, Incyte, Janssen, Kite, Karyopharm, Merck, MorphoSys, Roche/Genentech, Teva, Takeda, TG Therapeutics, Verastem
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine and Bio Ascend. The Postgraduate
Institute for Medicine is jointly accredited by the American Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy
Education (ACPE), and the American Nurses Credentialing Center (ANCC), to
provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Statement of Commercial Support
This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
info@bioascend.com
Activity Details
Expires: February 22, 2023
Jointly Provided By
The Postgraduate Institute for Medicine and Bio Ascend
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with DLBCL.
Learning Objectives
After participating in this activity, participants should be better able to:
- Appraise currently available multiagent chemo-immunotherapy approaches that are traditionally used for the treatment of patients with newly diagnosed DLBCL
- Assess the benefits and limitations of current therapeutic regimens for patients with newly diagnosed DLBCL and the need for novel approaches
- Evaluate the safety and efficacy of clinical trial results evaluating novel approaches to the upfront treatment of patients with DLBCL, including the use of novel agents and combinations
Activity Description
On-Topic Virtual Roundtable™ is an on-demand, accredited continuing education activity featuring three experts who provide expert summary and guidance on the use of current and emerging multiagent treatment regimens for patients with newly diagnosed DLBCL. This roundtable will summarize traditionally used chemo-immunotherapy regimens, limitations with currently available therapies, clinical data of emerging agents and combinations, and strategies for integrating novel regimens into practice as they become available.
Statement of Educational Need
The current standard of care of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in 2021 remains chemo-immunotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Although this modality is safe and effective, up to 45%-50% of patients will relapse. This underscores the need for novel treatment approaches for these patients with newly diagnosed disease. This activity will discuss ongoing efforts to improve upon the standard of care of patients with DLBCL to lengthen progression-free survival (PFS) and improve patient outcomes.
Topics Discussed
- Introduction and Overview of Traditional Regimens
- Limitations of Traditional Therapies
- Emerging Approaches for Frontline Treatment
- Integrating Novel Approaches in Clinical Practice & Key Takeaways
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Gilles Salles, MD, PhD
Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, New York
Consultant: AbbVie, Bayer, BeiGene, BMS/Celgene, Epizyme, Genentech/Roche, Genmab, Incyte, Janssen, Kite/Gilead, Loxo, Milteniy, MorphoSys, Novartis, Rapt, Regeneron, Takeda
Stock Ownership: Owkin

Department Chair, Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Grant/Research Support: AbbVie, Acerta, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, Pharmacyclics, TG Therapeutics, Burroughs Wellcome Fund, CPRIT, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation
Consultant/Advisory Board: AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche, Gilead, Karyopharm, MEI Pharmaceuticals, Pharmacyclics/Janssen, Spectrum

Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Vancouver, Canada
Grant/Research Support: Roche/Genentech, Teva
Consultant/Advisory Board: AbbVie, Acerta, Arigen, Apobiologix, AstraZeneca, Bristol Myers Squibb, Celgene, Gilead, Incyte, Janssen, Kite, Karyopharm, Merck, MorphoSys, Roche/Genentech, Teva, Takeda, TG Therapeutics, Verastem
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine and Bio Ascend. The Postgraduate
Institute for Medicine is jointly accredited by the American Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy
Education (ACPE), and the American Nurses Credentialing Center (ANCC), to
provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Statement of Commercial Support
This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
info@bioascend.com
Hematology Presentations

Current and Emerging Therapies for Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
StartActivity Details
Expires: September 22, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Transplantation, hematology, and hematology/oncology clinicians engaged in the care of patients with GVHD.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Utilize available therapeutic strategies for the prevention and treatment of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (alloHSCT)
- Implement current and emerging strategies to address unmet needs in the management of steroid-refractory acute GVHD in allogeneic HSCT
Activity Description
Allogeneic HSCT is a revolutionary therapeutic discovery, yet despite advances, the procedure still carries substantial risk for complications and death. Even with prophylactic measures, many patients will go on to develop acute graft-versus-host disease (aGVHD). While there are several agents available for the prevention and treatment of aGVHD, there are still many unmet needs. In this Clinical Reflections® activity, learners will be presented with 2 cases of aGVHD and challenged by expert faculty to reflect back on how they could have been better managed. Faculty will then discuss current guidelines; prevention and treatment options; and emerging agents for prevention, first-line therapy, and steroid-refractory aGVHD.
Faculty

Associate Professor, Medicine
Hematology/Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Assistant Professor, Pediatrics
Harvard Medical School
Medical Director, Clinical Research and Clinical Development
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, MA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Christine N. Duncan, MD, has relevant financial relationships with bluebird bio, Inc., Jazz Pharmaceuticals, Magenta Therapeutics, Novartis, Omeros, Tome Biosciences (Consultant).
Doris M. Ponce, MD, has relevant financial relationships with Incyte Corporation, Kadmon Corporation (Advisor); CareDx, Ceramedix, Evive Biotech, Kadmon Corporation (Consultant); Incyte Corporation (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support of improving
patient care, RMEI Medical Education, LLC is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from CSL Behring LLC.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Activity Details
Expires: September 22, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Transplantation, hematology, and hematology/oncology clinicians engaged in the care of patients with GVHD.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Utilize available therapeutic strategies for the prevention and treatment of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (alloHSCT)
- Implement current and emerging strategies to address unmet needs in the management of steroid-refractory acute GVHD in allogeneic HSCT
Activity Description
Allogeneic HSCT is a revolutionary therapeutic discovery, yet despite advances, the procedure still carries substantial risk for complications and death. Even with prophylactic measures, many patients will go on to develop acute graft-versus-host disease (aGVHD). While there are several agents available for the prevention and treatment of aGVHD, there are still many unmet needs. In this Clinical Reflections® activity, learners will be presented with 2 cases of aGVHD and challenged by expert faculty to reflect back on how they could have been better managed. Faculty will then discuss current guidelines; prevention and treatment options; and emerging agents for prevention, first-line therapy, and steroid-refractory aGVHD.
Faculty

Associate Professor, Medicine
Hematology/Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Assistant Professor, Pediatrics
Harvard Medical School
Medical Director, Clinical Research and Clinical Development
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, MA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Christine N. Duncan, MD, has relevant financial relationships with bluebird bio, Inc., Jazz Pharmaceuticals, Magenta Therapeutics, Novartis, Omeros, Tome Biosciences (Consultant).
Doris M. Ponce, MD, has relevant financial relationships with Incyte Corporation, Kadmon Corporation (Advisor); CareDx, Ceramedix, Evive Biotech, Kadmon Corporation (Consultant); Incyte Corporation (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support of improving
patient care, RMEI Medical Education, LLC is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from CSL Behring LLC.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Management of Waldenström’s Macroglobulinemia in the Era of Targeted Therapies
StartActivity Details
1.0 Contact Hour(s)
Expires: May 12, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of community oncologists, hematologists, hematologists/oncologists, oncology nurses, NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.
Learning Objectives
After completing this program, participants should be able to:
- Discuss the criteria for diagnosis and initiation of therapy for patients with Waldenström’s Macroglobulinemia, and use this information to guide initial workup and treatment decision-making
- Assess the safety and efficacy of practice-changing clinical trial findings of current and emerging agents for Waldenström’s Macroglobulinemia
- Integrate current guidelines, available clinical trial data, and real-world findings into individualized strategies for treatment selection, sequencing, and monitoring of Waldenström’s Macroglobulinemia
Activity Description
This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
The treatment of Waldenström’s Macroglobulinemia (WM) patients should be highly personalized, and the patient’s clinical presentation, comorbidities, genomic profile, and preferences, as well as toxicity of the treatment regimens, should be taken into account. Considering the continued evolution of therapeutic modalities and management strategies for WM and the information burden placed on busy community healthcare professionals who may have little to no experience with WM, expert guidance and interpretation of the clinical significance of emerging clinical data would benefit those caring for patients with WM, allowing for ease of assessment and incorporation into clinical practice.
Faculty

Professor of Medicine, Harvard Medical School
Director, Bing Center for Waldenström’s Macroglobulinemia
Dana Farber Cancer Center
Boston, MA
Dr. Treon has provided the following disclosure information:
- Research Support/P.I.: AbbVie/Pharmacyclics, Beigene, BMS, Eli Lilly
- Consultant: Janssen, AbbVie/Pharmacyclics, Beigene, BMS
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks for participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by an educational grant from Ascentage Pharma Group, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in healthcare and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: May 12, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of community oncologists, hematologists, hematologists/oncologists, oncology nurses, NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.
Learning Objectives
After completing this program, participants should be able to:
- Discuss the criteria for diagnosis and initiation of therapy for patients with Waldenström’s Macroglobulinemia, and use this information to guide initial workup and treatment decision-making
- Assess the safety and efficacy of practice-changing clinical trial findings of current and emerging agents for Waldenström’s Macroglobulinemia
- Integrate current guidelines, available clinical trial data, and real-world findings into individualized strategies for treatment selection, sequencing, and monitoring of Waldenström’s Macroglobulinemia
Activity Description
This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
The treatment of Waldenström’s Macroglobulinemia (WM) patients should be highly personalized, and the patient’s clinical presentation, comorbidities, genomic profile, and preferences, as well as toxicity of the treatment regimens, should be taken into account. Considering the continued evolution of therapeutic modalities and management strategies for WM and the information burden placed on busy community healthcare professionals who may have little to no experience with WM, expert guidance and interpretation of the clinical significance of emerging clinical data would benefit those caring for patients with WM, allowing for ease of assessment and incorporation into clinical practice.
Faculty

Professor of Medicine, Harvard Medical School
Director, Bing Center for Waldenström’s Macroglobulinemia
Dana Farber Cancer Center
Boston, MA
Dr. Treon has provided the following disclosure information:
- Research Support/P.I.: AbbVie/Pharmacyclics, Beigene, BMS, Eli Lilly
- Consultant: Janssen, AbbVie/Pharmacyclics, Beigene, BMS
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks for participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by an educational grant from Ascentage Pharma Group, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in healthcare and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com

Expert Perspectives on Optimizing Outcomes with the Latest Advances in Small Molecule Inhibitors for Chronic Lymphocytic Leukemia
StartActivity Details
1.0 Contact Hour(s)
Expires: April 11, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of community oncologists, hematology/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.
Learning Objectives
After completing this program, participants should be able to:
- Utilize testing for prognostic and predictive markers to stratify risk and optimize treatment selection for patients with CLL
- Employ the latest evidence and available guidelines to select among available therapeutic options in the first-line setting or for relapsed/refractory disease, including considerations for optimal sequencing of therapies
- Describe the clinical data regarding efficacy and safety of emerging therapies and approaches for the treatment of patients with CLL
- Outline acute and long-term safety considerations and factors influencing adherence to CLL treatment and evidence-based strategies to manage these considerations
Activity Description
This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with CLL. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
With the recent advances in targeted therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of new agents and combinations into the clinic have provided additional effective treatment options but have also created uncertainty over differences in patients who may benefit, efficacy of available and emerging agents, optimal sequencing and combinations, and safety among the available agents. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact outcomes for patients with CLL.
Faculty

Clinical Research Director, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Dr. Davids has provided the following disclosure information:
SAB/Consultant/Honoraria: AbbVie, BMS, Genentech, Janssen, Pharmacyclics, TG Therapeutics, Celgene, AstraZeneca, Eli Lilly, MEI Pharma, Merck, Adaptive Biosciences, BeiGene, Ascentage Pharma, Takeda, Aptitude Health, Research to Practice
Research funding: Genentech, Pharmacyclics, TG Therapeutics, MEI Pharma, Surface Oncology, AstraZeneca, Ascentage Pharma, Novartis
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from AbbVie and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: April 11, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of community oncologists, hematology/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with chronic lymphocytic leukemia.
Learning Objectives
After completing this program, participants should be able to:
- Utilize testing for prognostic and predictive markers to stratify risk and optimize treatment selection for patients with CLL
- Employ the latest evidence and available guidelines to select among available therapeutic options in the first-line setting or for relapsed/refractory disease, including considerations for optimal sequencing of therapies
- Describe the clinical data regarding efficacy and safety of emerging therapies and approaches for the treatment of patients with CLL
- Outline acute and long-term safety considerations and factors influencing adherence to CLL treatment and evidence-based strategies to manage these considerations
Activity Description
This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with CLL. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
With the recent advances in targeted therapies for CLL, the use of approved and investigational agents is anticipated to expand over the coming years. The introduction of new agents and combinations into the clinic have provided additional effective treatment options but have also created uncertainty over differences in patients who may benefit, efficacy of available and emerging agents, optimal sequencing and combinations, and safety among the available agents. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact outcomes for patients with CLL.
Faculty

Clinical Research Director, Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Dr. Davids has provided the following disclosure information:
SAB/Consultant/Honoraria: AbbVie, BMS, Genentech, Janssen, Pharmacyclics, TG Therapeutics, Celgene, AstraZeneca, Eli Lilly, MEI Pharma, Merck, Adaptive Biosciences, BeiGene, Ascentage Pharma, Takeda, Aptitude Health, Research to Practice
Research funding: Genentech, Pharmacyclics, TG Therapeutics, MEI Pharma, Surface Oncology, AstraZeneca, Ascentage Pharma, Novartis
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from AbbVie and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com

Expert Guidance on the Optimal Use of Current and Emerging BTK Inhibitors for Patients with CLL
StartActivity Details
Expires: March 23, 2023
Accredited By
The University of Nebraska Medical Center
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.
Learning Objectives
After participating in this activity, participants should be better able to:
- Identify various disease- and patient-related factors that impact the selection of BTK inhibitor use in patients with CLL
- Evaluate clinical trial data of BTK inhibitors that are currently approved for the treatment of patients with CLL
- Assess trial results of investigational BTK-based approaches to the treatment of CLL, including monotherapy and combination approaches
- Review strategies for improving patient outcomes, including optimal selection and sequencing of therapy, adverse event management, as well as oral adherence strategies
Activity Description
This webcast will provide expert guidance on how to correctly use current and emerging BTK inhibitors safely and effectively for patients with CLL and plan strategies for optimal integration of these novel agents into practice.
Statement of Educational Need
Major advances in the diagnosis and treatment of CLL have occurred in the past decade. In the future, studies will continue to BTK inhibitors have substantially altered the management, clinical course, and outcome of patients with CLL. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Significant efforts are underway to investigate the optimal combinations, timing, and sequencing of BTK inhibitors with other regimens and targeted agents, and to capitalize on the immunomodulatory modes of action of BTK inhibitors to correct tumor-induced immune defects and to achieve long-lasting tumor control.
Agenda
- Welcome & Introductions
- Rationale for Targeting Bruton Tyrosine Kinase (BTK) in Patients With CLL
- Currently Available BTK Inhibitor-Based Strategies: Phase 3 Studies
- Future Directions and Emerging Data of BTK Inhibitor Therapy
- Considerations for Improving Patient Outcomes
- Conclusions
Faculty and Planning Committee Disclosures
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts
Disclosures
Contracted Research & Publishing: AbbVie Inc., Ascentage
Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface
Oncology, TG Therapeutics, Verastem, Inc.
Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research To Practice, TG Therapeutics, Verastem, Inc.
Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Patti Bunyasaranand, MS; Dru Dace, PhD; Kraig
Steubing
Continuing Education
In support
of improving patient care, this activity has been planned and implemented by
the University of Nebraska Medical Center and Bio Ascend. The University of
Nebraska Medical Center is jointly accredited by the Accreditation Council
for Continuing Medical Education (ACCME), the Accreditation Council for
Pharmacy Education (ACPE), and the American Nurses Credentialing Center
(ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating in and receiving continuing education
credit for this activity. During the accredited period, participants must: 1)
read the educational objectives and conflict of interest disclosures; 2)
study the educational activity; 3) complete the pre- and post-test and
evaluation.
Participants who complete the educational activity, pre- and post-test, and
evaluation will receive an accredited continuing education credit
certificate.
Statement of Commercial Support
Educational grant support provided by BeiGene, Ltd. and Pharmacyclics LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.
Contact Information for Questions About the Activity
info@bioascend.com
Activity Details
Expires: March 23, 2023
Accredited By
The University of Nebraska Medical Center
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.
Learning Objectives
After participating in this activity, participants should be better able to:
- Identify various disease- and patient-related factors that impact the selection of BTK inhibitor use in patients with CLL
- Evaluate clinical trial data of BTK inhibitors that are currently approved for the treatment of patients with CLL
- Assess trial results of investigational BTK-based approaches to the treatment of CLL, including monotherapy and combination approaches
- Review strategies for improving patient outcomes, including optimal selection and sequencing of therapy, adverse event management, as well as oral adherence strategies
Activity Description
This webcast will provide expert guidance on how to correctly use current and emerging BTK inhibitors safely and effectively for patients with CLL and plan strategies for optimal integration of these novel agents into practice.
Statement of Educational Need
Major advances in the diagnosis and treatment of CLL have occurred in the past decade. In the future, studies will continue to BTK inhibitors have substantially altered the management, clinical course, and outcome of patients with CLL. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Significant efforts are underway to investigate the optimal combinations, timing, and sequencing of BTK inhibitors with other regimens and targeted agents, and to capitalize on the immunomodulatory modes of action of BTK inhibitors to correct tumor-induced immune defects and to achieve long-lasting tumor control.
Agenda
- Welcome & Introductions
- Rationale for Targeting Bruton Tyrosine Kinase (BTK) in Patients With CLL
- Currently Available BTK Inhibitor-Based Strategies: Phase 3 Studies
- Future Directions and Emerging Data of BTK Inhibitor Therapy
- Considerations for Improving Patient Outcomes
- Conclusions
Faculty and Planning Committee Disclosures
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts
Disclosures
Contracted Research & Publishing: AbbVie Inc., Ascentage
Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface
Oncology, TG Therapeutics, Verastem, Inc.
Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research To Practice, TG Therapeutics, Verastem, Inc.
Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Patti Bunyasaranand, MS; Dru Dace, PhD; Kraig
Steubing
Continuing Education
In support
of improving patient care, this activity has been planned and implemented by
the University of Nebraska Medical Center and Bio Ascend. The University of
Nebraska Medical Center is jointly accredited by the Accreditation Council
for Continuing Medical Education (ACCME), the Accreditation Council for
Pharmacy Education (ACPE), and the American Nurses Credentialing Center
(ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating in and receiving continuing education
credit for this activity. During the accredited period, participants must: 1)
read the educational objectives and conflict of interest disclosures; 2)
study the educational activity; 3) complete the pre- and post-test and
evaluation.
Participants who complete the educational activity, pre- and post-test, and
evaluation will receive an accredited continuing education credit
certificate.
Statement of Commercial Support
Educational grant support provided by BeiGene, Ltd. and Pharmacyclics LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.
Contact Information for Questions About the Activity
info@bioascend.com

Understanding Evolving Treatment Strategies in Newly Diagnosed Multiple Myeloma Patients
StartActivity Details
1.0 Contact Hour(s)
Expires: March 20, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of community oncologists, hematology/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with newly diagnosed multiple myeloma.
Learning Objectives
After completing this program, participants should be able to:
- Review key advances in the treatment and management of newly diagnosed multiple myeloma (NDMM) and their impact on clinical practice
- Incorporate guideline-directed evidence-based best practices, taking into consideration patient-, disease-, and treatment-related factors to individualize care for NDMM patients
- Describe promising emerging therapies for the treatment of NDMM and their potential roles in the context of existing NDMM treatment paradigms
- Identify strategies to incorporate optimal treatment administration for NDMM patients
Activity Description
This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating newly diagnosed multiple myeloma patients. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
With changing guidelines, evolving concepts in diagnosis, treatment, and management of newly diagnosed multiple myeloma (NDMM), recently approved combination regimens and delivery formulations, and the introduction of novel agents and combination to the clinic, there are ongoing questions regarding the optimal treatment strategies for patients. Clinicians require expert guidance to actualize recent clinical advances into real-world clinical practice to optimize outcomes for their NDMM patients.
Faculty

Assistant Professor of Medicine
University of Chicago Medical Center
Chicago, Illinois
Dr. Derman has provided the following disclosure information:
Advisory Board: Sanofi, Janssen
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and the Leukemia Research Foundation.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: March 20, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of community oncologists, hematology/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with newly diagnosed multiple myeloma.
Learning Objectives
After completing this program, participants should be able to:
- Review key advances in the treatment and management of newly diagnosed multiple myeloma (NDMM) and their impact on clinical practice
- Incorporate guideline-directed evidence-based best practices, taking into consideration patient-, disease-, and treatment-related factors to individualize care for NDMM patients
- Describe promising emerging therapies for the treatment of NDMM and their potential roles in the context of existing NDMM treatment paradigms
- Identify strategies to incorporate optimal treatment administration for NDMM patients
Activity Description
This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating newly diagnosed multiple myeloma patients. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
With changing guidelines, evolving concepts in diagnosis, treatment, and management of newly diagnosed multiple myeloma (NDMM), recently approved combination regimens and delivery formulations, and the introduction of novel agents and combination to the clinic, there are ongoing questions regarding the optimal treatment strategies for patients. Clinicians require expert guidance to actualize recent clinical advances into real-world clinical practice to optimize outcomes for their NDMM patients.
Faculty

Assistant Professor of Medicine
University of Chicago Medical Center
Chicago, Illinois
Dr. Derman has provided the following disclosure information:
Advisory Board: Sanofi, Janssen
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and the Leukemia Research Foundation.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com

Utilizing Real World Evidence: Focus on Multiple Myeloma in Older Adults
StartActivity Details
1.0 Contact Hour(s)
Expires: February 28, 2023
Provider Statement
This CME activity for ACCME credit is provided by Integrity Continuing Education, Inc.
This CE activity for ANCC credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.
Statement of Commercial Support
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Target Audience
This educational activity has been designed to meet the needs of hematologist/oncologists, medical oncologists, physician assistants, nurse practitioners, and advanced practice nurses who treat and manage patients with multiple myeloma.
Program Overview
Evidence has demonstrated that undertreatment of fit elderly multiple myeloma (MM) patients occurs more frequently than overtreatment. While overtreatment of frail MM patients can induce unnecessary morbidity and mortality, an appropriate assessment for frailty is key to determine whether the patient is actually frail or in fact fit. This step ensures optimal outcomes and improved health-related quality of life.

This In The Clinic activity features a discussion on proper assessment of older MM patients, different scoring systems, the role of real-world evidence (RWE), and trials that support the use of RWE. The clinical case scenarios will allow participants to utilize information from the discussions. A simplified, downloadable frailty scoring tool is also included.
Learning Objectives
- ASSESS patients for fitness/frailty to select appropriate treatment based on individual results
- EVALUATE patient data, including real-world data such as patient reported outcomes and assessment scores, to determine the most appropriate treatment regimens
- IDENTIFY strategies for managing toxicities and comorbidities associated with MM in older patients
Moderator

Chief Innovation Officer
Getz Family Professor of Cancer
Department of Hematology/Oncology
Distinguished Mayo Clinic Investigator
Phoenix, Arizona
Faculty Presenters

Professor of Medicine
Director, Myeloma Clinical Program
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Florence Maude Thomas Cancer Research Professor
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Case Study Development
Hematology Oncologist
Juravinski Cancer Centre
Assistant Professor of Oncology
McMaster University
Ontario, Canada
Disclosure of Conflicts of Interest
Integrity Continuing Education, Inc. and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
Faith Davies, MBBCh, MRCP, MD, FRCPath
Consultant: AbbVie, Amgen, Bristol Myers Squibb/Celgene,
GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Takeda
Rafael Fonseca, MD
Consultant: AbbVie, Aduro, Amgen, Bayer, Bristol Myers Squibb,
Celgene, GlaxoSmithKline, Janssen, Juno, Kite, Merck, Novartis, OncoTracker,
Pharmacyclics, Sanofi, Takeda
Scientific Advisory Boards: Adaptive Biotechnologies,
OncoTracker
Hira Mian, MD
Research Funding: Janssen
Advisor/Speaker: Amgen, Bristol Myers Squibb, GlaxoSmithKline,
Janssen, Sanofi, Takeda
Robert Orlowski, MD, PhD
Consultant: AbbVie, Bristol Myers Squibb, GlaxoSmithKline
Biologicals, Karyopharm Therapeutics, Inc., Meridian Therapeutics, Monte Rosa
Therapeutics, Neoleukin Corporation, Oncopeptides AB, Regeneron
Pharmaceuticals, Inc.
The following project managers/planners: Lindsay Borvansky, Ashley Cann, Samuel Ciociola, Donna Fausak, Andrea Funk, Liddy Knight, David Lemler, PhD, and Rhys Williams, RN, MSN, FNP, reported that they or their spouses/life partners have no financial relationships or relationships to products or devices with ineligible companies related to the content of this CE activity.
Physician Continuing Education
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation
Council for Continuing Medical Education (ACCME) to provide continuing
medical education for physicians.
Credit Designation
Integrity Continuing Education, Inc. designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 Credit™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.0 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CE/CME credit for this activity. During the period of February 28, 2022, through February 28, 2023, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. Integrity
Continuing Education, Inc. and Global Education Group do not recommend the
use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty
and do not necessarily represent the views of any organization associated
with this activity. Please refer to the official prescribing information for
each product for discussion of approved indications, contraindications, and
warnings.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.
For information about ANCC accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Activity Details
1.0 Contact Hour(s)
Expires: February 28, 2023
Provider Statement
This CME activity for ACCME credit is provided by Integrity Continuing Education, Inc.
This CE activity for ANCC credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.
Statement of Commercial Support
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Target Audience
This educational activity has been designed to meet the needs of hematologist/oncologists, medical oncologists, physician assistants, nurse practitioners, and advanced practice nurses who treat and manage patients with multiple myeloma.
Program Overview
Evidence has demonstrated that undertreatment of fit elderly multiple myeloma (MM) patients occurs more frequently than overtreatment. While overtreatment of frail MM patients can induce unnecessary morbidity and mortality, an appropriate assessment for frailty is key to determine whether the patient is actually frail or in fact fit. This step ensures optimal outcomes and improved health-related quality of life.

This In The Clinic activity features a discussion on proper assessment of older MM patients, different scoring systems, the role of real-world evidence (RWE), and trials that support the use of RWE. The clinical case scenarios will allow participants to utilize information from the discussions. A simplified, downloadable frailty scoring tool is also included.
Learning Objectives
- ASSESS patients for fitness/frailty to select appropriate treatment based on individual results
- EVALUATE patient data, including real-world data such as patient reported outcomes and assessment scores, to determine the most appropriate treatment regimens
- IDENTIFY strategies for managing toxicities and comorbidities associated with MM in older patients
Moderator

Chief Innovation Officer
Getz Family Professor of Cancer
Department of Hematology/Oncology
Distinguished Mayo Clinic Investigator
Phoenix, Arizona
Faculty Presenters

Professor of Medicine
Director, Myeloma Clinical Program
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Florence Maude Thomas Cancer Research Professor
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Case Study Development
Hematology Oncologist
Juravinski Cancer Centre
Assistant Professor of Oncology
McMaster University
Ontario, Canada
Disclosure of Conflicts of Interest
Integrity Continuing Education, Inc. and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
Faith Davies, MBBCh, MRCP, MD, FRCPath
Consultant: AbbVie, Amgen, Bristol Myers Squibb/Celgene,
GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Takeda
Rafael Fonseca, MD
Consultant: AbbVie, Aduro, Amgen, Bayer, Bristol Myers Squibb,
Celgene, GlaxoSmithKline, Janssen, Juno, Kite, Merck, Novartis, OncoTracker,
Pharmacyclics, Sanofi, Takeda
Scientific Advisory Boards: Adaptive Biotechnologies,
OncoTracker
Hira Mian, MD
Research Funding: Janssen
Advisor/Speaker: Amgen, Bristol Myers Squibb, GlaxoSmithKline,
Janssen, Sanofi, Takeda
Robert Orlowski, MD, PhD
Consultant: AbbVie, Bristol Myers Squibb, GlaxoSmithKline
Biologicals, Karyopharm Therapeutics, Inc., Meridian Therapeutics, Monte Rosa
Therapeutics, Neoleukin Corporation, Oncopeptides AB, Regeneron
Pharmaceuticals, Inc.
The following project managers/planners: Lindsay Borvansky, Ashley Cann, Samuel Ciociola, Donna Fausak, Andrea Funk, Liddy Knight, David Lemler, PhD, and Rhys Williams, RN, MSN, FNP, reported that they or their spouses/life partners have no financial relationships or relationships to products or devices with ineligible companies related to the content of this CE activity.
Physician Continuing Education
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation
Council for Continuing Medical Education (ACCME) to provide continuing
medical education for physicians.
Credit Designation
Integrity Continuing Education, Inc. designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 Credit™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.0 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CE/CME credit for this activity. During the period of February 28, 2022, through February 28, 2023, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. Integrity
Continuing Education, Inc. and Global Education Group do not recommend the
use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty
and do not necessarily represent the views of any organization associated
with this activity. Please refer to the official prescribing information for
each product for discussion of approved indications, contraindications, and
warnings.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.
For information about ANCC accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

On-Topic Virtual Roundtable™: From R-CHOP to Beyond – Emerging Strategies to Prevent Disease Progression in Patients with Newly Diagnosed DLBCL
StartActivity Details
Expires: February 22, 2023
Jointly Provided By
The Postgraduate Institute for Medicine and Bio Ascend
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with DLBCL.
Learning Objectives
After participating in this activity, participants should be better able to:
- Appraise currently available multiagent chemo-immunotherapy approaches that are traditionally used for the treatment of patients with newly diagnosed DLBCL
- Assess the benefits and limitations of current therapeutic regimens for patients with newly diagnosed DLBCL and the need for novel approaches
- Evaluate the safety and efficacy of clinical trial results evaluating novel approaches to the upfront treatment of patients with DLBCL, including the use of novel agents and combinations
Activity Description
On-Topic Virtual Roundtable™ is an on-demand, accredited continuing education activity featuring three experts who provide expert summary and guidance on the use of current and emerging multiagent treatment regimens for patients with newly diagnosed DLBCL. This roundtable will summarize traditionally used chemo-immunotherapy regimens, limitations with currently available therapies, clinical data of emerging agents and combinations, and strategies for integrating novel regimens into practice as they become available.
Statement of Educational Need
The current standard of care of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in 2021 remains chemo-immunotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Although this modality is safe and effective, up to 45%-50% of patients will relapse. This underscores the need for novel treatment approaches for these patients with newly diagnosed disease. This activity will discuss ongoing efforts to improve upon the standard of care of patients with DLBCL to lengthen progression-free survival (PFS) and improve patient outcomes.
Topics Discussed
- Introduction and Overview of Traditional Regimens
- Limitations of Traditional Therapies
- Emerging Approaches for Frontline Treatment
- Integrating Novel Approaches in Clinical Practice & Key Takeaways
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Gilles Salles, MD, PhD
Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, New York
Consultant: AbbVie, Bayer, BeiGene, BMS/Celgene, Epizyme, Genentech/Roche, Genmab, Incyte, Janssen, Kite/Gilead, Loxo, Milteniy, MorphoSys, Novartis, Rapt, Regeneron, Takeda
Stock Ownership: Owkin

Department Chair, Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Grant/Research Support: AbbVie, Acerta, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, Pharmacyclics, TG Therapeutics, Burroughs Wellcome Fund, CPRIT, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation
Consultant/Advisory Board: AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche, Gilead, Karyopharm, MEI Pharmaceuticals, Pharmacyclics/Janssen, Spectrum

Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Vancouver, Canada
Grant/Research Support: Roche/Genentech, Teva
Consultant/Advisory Board: AbbVie, Acerta, Arigen, Apobiologix, AstraZeneca, Bristol Myers Squibb, Celgene, Gilead, Incyte, Janssen, Kite, Karyopharm, Merck, MorphoSys, Roche/Genentech, Teva, Takeda, TG Therapeutics, Verastem
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine and Bio Ascend. The Postgraduate
Institute for Medicine is jointly accredited by the American Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy
Education (ACPE), and the American Nurses Credentialing Center (ANCC), to
provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Statement of Commercial Support
This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
info@bioascend.com
Activity Details
Expires: February 22, 2023
Jointly Provided By
The Postgraduate Institute for Medicine and Bio Ascend
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with DLBCL.
Learning Objectives
After participating in this activity, participants should be better able to:
- Appraise currently available multiagent chemo-immunotherapy approaches that are traditionally used for the treatment of patients with newly diagnosed DLBCL
- Assess the benefits and limitations of current therapeutic regimens for patients with newly diagnosed DLBCL and the need for novel approaches
- Evaluate the safety and efficacy of clinical trial results evaluating novel approaches to the upfront treatment of patients with DLBCL, including the use of novel agents and combinations
Activity Description
On-Topic Virtual Roundtable™ is an on-demand, accredited continuing education activity featuring three experts who provide expert summary and guidance on the use of current and emerging multiagent treatment regimens for patients with newly diagnosed DLBCL. This roundtable will summarize traditionally used chemo-immunotherapy regimens, limitations with currently available therapies, clinical data of emerging agents and combinations, and strategies for integrating novel regimens into practice as they become available.
Statement of Educational Need
The current standard of care of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in 2021 remains chemo-immunotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Although this modality is safe and effective, up to 45%-50% of patients will relapse. This underscores the need for novel treatment approaches for these patients with newly diagnosed disease. This activity will discuss ongoing efforts to improve upon the standard of care of patients with DLBCL to lengthen progression-free survival (PFS) and improve patient outcomes.
Topics Discussed
- Introduction and Overview of Traditional Regimens
- Limitations of Traditional Therapies
- Emerging Approaches for Frontline Treatment
- Integrating Novel Approaches in Clinical Practice & Key Takeaways
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Gilles Salles, MD, PhD
Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, New York
Consultant: AbbVie, Bayer, BeiGene, BMS/Celgene, Epizyme, Genentech/Roche, Genmab, Incyte, Janssen, Kite/Gilead, Loxo, Milteniy, MorphoSys, Novartis, Rapt, Regeneron, Takeda
Stock Ownership: Owkin

Department Chair, Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Grant/Research Support: AbbVie, Acerta, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, Pharmacyclics, TG Therapeutics, Burroughs Wellcome Fund, CPRIT, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation
Consultant/Advisory Board: AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche, Gilead, Karyopharm, MEI Pharmaceuticals, Pharmacyclics/Janssen, Spectrum

Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Vancouver, Canada
Grant/Research Support: Roche/Genentech, Teva
Consultant/Advisory Board: AbbVie, Acerta, Arigen, Apobiologix, AstraZeneca, Bristol Myers Squibb, Celgene, Gilead, Incyte, Janssen, Kite, Karyopharm, Merck, MorphoSys, Roche/Genentech, Teva, Takeda, TG Therapeutics, Verastem
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine and Bio Ascend. The Postgraduate
Institute for Medicine is jointly accredited by the American Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy
Education (ACPE), and the American Nurses Credentialing Center (ANCC), to
provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Statement of Commercial Support
This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
info@bioascend.com

Emerging Cellular and Targeted Therapy Options for the Management of Large B-Cell Lymphoma
StartActivity Details
1.0 Contact Hour(s)
Expires: February 21, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with large B-cell lymphoma.
Learning Objectives
After completing this program, participants should be able to:
- Analyze the latest developments in cellular and targeted therapies used for the treatment of LBCL, as well as how these approaches fit into the current treatment landscape
- Assess ongoing clinical trials using cellular and targeted therapies to treat LBCL, including studies focused on using cellular and targeted therapies in the frontline setting
- Outline adverse effects associated with cellular and targeted therapies and describe effective approaches to appropriately manage these effects
- Identify patients with LBCL who are candidates for cellular and targeted therapy and formulate individualized treatment plans based on intrinsic characteristics of the patient, the disease, and the treatment
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of large B-cell lymphoma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with LBCL and the clinical utility of agents that could significantly impact patient outcomes. With the recent advances in cellular and targeted therapies for LBCL, the use of approved and investigational agents is anticipated to expand over the coming years. Clinicians must be up-to-date on the efficacy and safety profile of currently approved and investigational agents to offer patients the best clinical outcomes.
Faculty

Medical Director, Immune Effector Cell Therapy Program
Senior Physician
Assistant Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA
Dr. Jacobson has provided the following disclosure information:
- Consulting for Kite/Gilead, BMS/Celgene, Novartis, Precision Biosciences, Nkarta, Lonza, bluebird bio, AbbVie, Ipsen
- Research funding from Kite/Gilead, Pfizer
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks for participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from ADC Therapeutics Inc., Bristol Myers Squibb, Genentech, Genmab US, Inc., and Incyte who have had no influence on, control of, nor input into the development or performance of the activity.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: February 21, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with large B-cell lymphoma.
Learning Objectives
After completing this program, participants should be able to:
- Analyze the latest developments in cellular and targeted therapies used for the treatment of LBCL, as well as how these approaches fit into the current treatment landscape
- Assess ongoing clinical trials using cellular and targeted therapies to treat LBCL, including studies focused on using cellular and targeted therapies in the frontline setting
- Outline adverse effects associated with cellular and targeted therapies and describe effective approaches to appropriately manage these effects
- Identify patients with LBCL who are candidates for cellular and targeted therapy and formulate individualized treatment plans based on intrinsic characteristics of the patient, the disease, and the treatment
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of large B-cell lymphoma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with LBCL and the clinical utility of agents that could significantly impact patient outcomes. With the recent advances in cellular and targeted therapies for LBCL, the use of approved and investigational agents is anticipated to expand over the coming years. Clinicians must be up-to-date on the efficacy and safety profile of currently approved and investigational agents to offer patients the best clinical outcomes.
Faculty

Medical Director, Immune Effector Cell Therapy Program
Senior Physician
Assistant Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA
Dr. Jacobson has provided the following disclosure information:
- Consulting for Kite/Gilead, BMS/Celgene, Novartis, Precision Biosciences, Nkarta, Lonza, bluebird bio, AbbVie, Ipsen
- Research funding from Kite/Gilead, Pfizer
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks for participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by an educational grant from ADC Therapeutics Inc., Bristol Myers Squibb, Genentech, Genmab US, Inc., and Incyte who have had no influence on, control of, nor input into the development or performance of the activity.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com

Expert Insights − Experts Debate: Treatment Decisions in Relapsed/Refractory Multiple Myeloma
StartActivity Details
Expires: February 2, 2023
Accredited By
The University of Nebraska Medical Center
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Incorporate minimal residual disease assessment when evaluating prognosis and potential relapse
- Evaluate treatment approaches for patients with relapsed and/or refractory MM, specifically the decision to include a monoclonal bispecific antibody, or antibody-drug conjugate, CAR T cell therapy, and combination with other agents for triplet therapy
- Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with MM
- Discuss the results of clinical trials that are investigating emerging novel agents in patients with MM
Activity Description
Expert Insights is an interview involving two renowned experts actively engaged in the treatment of patients with relapsed/refractory multiple myeloma. Don’t miss the opportunity to watch Drs. Sagar Lonial and Krina Patel as they provide key highlights from a satellite symposium preceding the 2021 ASH Annual Meeting.
Statement of Educational Need
The treatment of multiple myeloma (MM) has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, particularly in the relapsed/refractory (RR) MM setting, questions of ideal sequencing of agents, management of adverse events, and incorporating emerging data on investigational agents will require expert guidance and interpretation of newly released data. The goal of this satellite symposium is to provide actionable information and knowledge that will ensure clinicians use the most up-to-date strategies for treating patients with RR MM.
Faculty and Planning Committee Disclosures
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
Faculty

Chief Medical Officer
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Atlanta, Georgia
Consulting Fees: Amgen Inc., Bluebird, Bristol Myers Squibb Company, Celgene Corporation, Genentech, Novartis, Sanofi, Takeda Oncology
Other: Board of Directors TG Therapeutics with stock

Associate Professor, Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Consulting Fees: Arcellx, Bristol Myers Squibb Company, Janssen, Pfizer
Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Jennifer Bechan, CMP, HMCC; Dru Dace, PhD; Kraig
Steubing
Continuing Education
In support of
improving patient care, this activity has been planned and implemented by the
University of Nebraska Medical Center and Bio Ascend. The University of
Nebraska Medical Center is jointly accredited by the Accreditation Council
for Continuing Medical Education (ACCME), the Accreditation Council for
Pharmacy Education (ACPE), and the American Nurses Credentialing Center
(ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating in and receiving continuing education credit for this activity. During the accredited period, participants must: 1) read the educational objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive an accredited continuing education credit certificate.
Statement of Commercial Support
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Legend Biotech, Oncopeptides, Inc., and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.
Contact Information for Questions About the Activity
info@bioascend.com
Activity Details
Expires: February 2, 2023
Accredited By
The University of Nebraska Medical Center
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Incorporate minimal residual disease assessment when evaluating prognosis and potential relapse
- Evaluate treatment approaches for patients with relapsed and/or refractory MM, specifically the decision to include a monoclonal bispecific antibody, or antibody-drug conjugate, CAR T cell therapy, and combination with other agents for triplet therapy
- Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with MM
- Discuss the results of clinical trials that are investigating emerging novel agents in patients with MM
Activity Description
Expert Insights is an interview involving two renowned experts actively engaged in the treatment of patients with relapsed/refractory multiple myeloma. Don’t miss the opportunity to watch Drs. Sagar Lonial and Krina Patel as they provide key highlights from a satellite symposium preceding the 2021 ASH Annual Meeting.
Statement of Educational Need
The treatment of multiple myeloma (MM) has changed dramatically in the past decade. While MM remains an incurable disease, advances in therapy have resulted in a marked improvement in overall survival (OS). New therapies have been approved including novel proteasome inhibitors and antibodies. With so many new available agents, particularly in the relapsed/refractory (RR) MM setting, questions of ideal sequencing of agents, management of adverse events, and incorporating emerging data on investigational agents will require expert guidance and interpretation of newly released data. The goal of this satellite symposium is to provide actionable information and knowledge that will ensure clinicians use the most up-to-date strategies for treating patients with RR MM.
Faculty and Planning Committee Disclosures
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
Faculty

Chief Medical Officer
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Atlanta, Georgia
Consulting Fees: Amgen Inc., Bluebird, Bristol Myers Squibb Company, Celgene Corporation, Genentech, Novartis, Sanofi, Takeda Oncology
Other: Board of Directors TG Therapeutics with stock

Associate Professor, Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Consulting Fees: Arcellx, Bristol Myers Squibb Company, Janssen, Pfizer
Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Jennifer Bechan, CMP, HMCC; Dru Dace, PhD; Kraig
Steubing
Continuing Education
In support of
improving patient care, this activity has been planned and implemented by the
University of Nebraska Medical Center and Bio Ascend. The University of
Nebraska Medical Center is jointly accredited by the Accreditation Council
for Continuing Medical Education (ACCME), the Accreditation Council for
Pharmacy Education (ACPE), and the American Nurses Credentialing Center
(ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating in and receiving continuing education credit for this activity. During the accredited period, participants must: 1) read the educational objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive an accredited continuing education credit certificate.
Statement of Commercial Support
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Legend Biotech, Oncopeptides, Inc., and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.
Contact Information for Questions About the Activity
info@bioascend.com

Podium to Practice: Recent Updates on the Treatment of Myeloproliferative Neoplasms – Highlights from the 2021 Hematology Annual Meeting
StartActivity Details
Expires: February 2, 2023
Jointly Provided By
The Postgraduate Institute for Medicine and Bio Ascend
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MPNs.
Learning Objectives
After participating in this activity, participants should be better able to:
- Identify treatment goals for myeloproliferative neoplasms that incorporate disease-modifying therapies based on the latest available clinical data
- Develop strategies to incorporate disease-modifying therapies and strive for deeper responses in patients with myeloproliferative neoplasms
- Discuss the emerging results of clinical trials that are investigating therapies in myeloproliferative neoplasms
Activity Description
Podium to Practice™ is an exclusive accredited continuing education activity featuring two myeloproliferative neoplasms (MPN) experts who provide expert summary and guidance on the optimal use of current and emerging therapies and interpretation of data presented during the 2021 ASH Annual Meeting.
Statement of Educational Need
In recent years, there have been major advances in our understanding of the underlying genetic changes that drive the development of MPNs, particularly with the discovery of mutations in the Janus kinase 2 (JAK2), thrombopoietin receptor (MPL), and calreticulin (CALR) genes. JAK inhibitors represent a shift in the treatment paradigm from largely managing lifestyle and cardiovascular risk factors and addressing the effects of the disease, to attempting modification of the disease process itself. Despite these advances, nearly all treatment options for MPNs are not curative. Therefore, reduction of symptom burden, and thereby the impact of MPNs on QoL, is critical and should be considered a major goal of treatment. With a robust pipeline of new disease-modifying therapies, a clinical question of whether to aim for a deeper response is emerging.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

John O. Mascarenhas, MD
Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Tisch Cancer Institute, Division of Hematology/Oncology
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York
Consultant: AbbVie, Bristol Myers Squibb, Celgene Corporation, Constellation, CTI BioPharma, Geron, Incyte Corporation, Kartos, Novartis, PharmaEssentia, Roche, Sierra ONC
Contracted Research: AbbVie, Bristol Myers Squibb, Celgene Corporation, CTI BioPharma, Geron, Incyte Corporation, Kartos, Novartis, PharmaEssentia, Roche

Professor of Hematology
Careggi University Hospital
University of Florence
Florence, Italy
Consultant: AbbVie, Blueprint, Bristol Myers Squibb, GlaxoSmithKline, Incyte, Novartis, Roche
Contracted Research: AbbVie, Blueprint, Bristol Myers Squibb, GlaxoSmithKline, Incyte, Novartis, Roche
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine and Bio Ascend. The Postgraduate
Institute for Medicine is jointly accredited by the American Council for
Continuing Medical Education (ACCME), Accreditation Council for Pharmacy
Education (ACPE), and the American Nurses Credentialing Center (ANCC), to
provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Statement of Commercial Support
This activity is supported by an independent educational grant from CTI BioPharma.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
info@bioascend.com
Activity Details
Expires: February 2, 2023
Jointly Provided By
The Postgraduate Institute for Medicine and Bio Ascend
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MPNs.
Learning Objectives
After participating in this activity, participants should be better able to:
- Identify treatment goals for myeloproliferative neoplasms that incorporate disease-modifying therapies based on the latest available clinical data
- Develop strategies to incorporate disease-modifying therapies and strive for deeper responses in patients with myeloproliferative neoplasms
- Discuss the emerging results of clinical trials that are investigating therapies in myeloproliferative neoplasms
Activity Description
Podium to Practice™ is an exclusive accredited continuing education activity featuring two myeloproliferative neoplasms (MPN) experts who provide expert summary and guidance on the optimal use of current and emerging therapies and interpretation of data presented during the 2021 ASH Annual Meeting.
Statement of Educational Need
In recent years, there have been major advances in our understanding of the underlying genetic changes that drive the development of MPNs, particularly with the discovery of mutations in the Janus kinase 2 (JAK2), thrombopoietin receptor (MPL), and calreticulin (CALR) genes. JAK inhibitors represent a shift in the treatment paradigm from largely managing lifestyle and cardiovascular risk factors and addressing the effects of the disease, to attempting modification of the disease process itself. Despite these advances, nearly all treatment options for MPNs are not curative. Therefore, reduction of symptom burden, and thereby the impact of MPNs on QoL, is critical and should be considered a major goal of treatment. With a robust pipeline of new disease-modifying therapies, a clinical question of whether to aim for a deeper response is emerging.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

John O. Mascarenhas, MD
Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Tisch Cancer Institute, Division of Hematology/Oncology
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York
Consultant: AbbVie, Bristol Myers Squibb, Celgene Corporation, Constellation, CTI BioPharma, Geron, Incyte Corporation, Kartos, Novartis, PharmaEssentia, Roche, Sierra ONC
Contracted Research: AbbVie, Bristol Myers Squibb, Celgene Corporation, CTI BioPharma, Geron, Incyte Corporation, Kartos, Novartis, PharmaEssentia, Roche

Professor of Hematology
Careggi University Hospital
University of Florence
Florence, Italy
Consultant: AbbVie, Blueprint, Bristol Myers Squibb, GlaxoSmithKline, Incyte, Novartis, Roche
Contracted Research: AbbVie, Blueprint, Bristol Myers Squibb, GlaxoSmithKline, Incyte, Novartis, Roche
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine and Bio Ascend. The Postgraduate
Institute for Medicine is jointly accredited by the American Council for
Continuing Medical Education (ACCME), Accreditation Council for Pharmacy
Education (ACPE), and the American Nurses Credentialing Center (ANCC), to
provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for
a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Statement of Commercial Support
This activity is supported by an independent educational grant from CTI BioPharma.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
info@bioascend.com